Literature DB >> 7479362

The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases.

A J Martínez1, M Sell, T Mitrovics, G Stoltenburg-Didinger, J R Iglesias-Rozas, M A Giraldo-Velásquez, G Gosztonyi, V Schneider, J Cervós-Navarro.   

Abstract

The brains of 200 patients who died with Acquired Immunodeficiency Syndrome (AIDS) from Berlin were examined retrospectively. This study was specifically intended to evaluate and document the prevalence of neuropathologic abnormalities, establishing the frequency of the various types of structural lesions, their combinations, their relative incidence, and the risk factors involved in different age groups. The data were compared and contrasted with the findings reported from other parts of the world and other German cities. It was found that the mean age of this group of patients was 41.4 years old, 75% were homosexual/bisexuals (H/B) and 18.5% were drug abusers (DA). Only 5.5% were women. Brain parenchymal changes, called in this report, HIV-related encephalopathy (HIVRE), characterized by vacuolization or spongy changes and astrocytosis in the subcortical white matter, and occasionally in gray matter, were found in 67 patients (33.5%). Drug abusers had a higher incidence of HIVRE (59.5%) compared with homosexual/bisexuals (28%). This is statistically significant (p < 0.0005). CMV encephalitis was found in 26 patients (13%) (8% of the drug abusers in contrast to 13% in the homosexual/bisexuals group). Primary central nervous system lymphoma (PCNSL) was seen in 28 patients (14%) regardless of the risk factor involved. 20 (13%) of the 150 H/B and 3 (8%) of the 37 DA had CMV encephalitis. Of the 150 H/B, 24 (16%) had PCNSL compared with only 4 of 37 (11%) of the DA. A significant incidence of opportunistic infections, both protozoal and viral was found in all groups. Cerebral toxoplasmosis occurred in 68 patients (34%). Microglial (phagocytic) nodules, probably related to CMV or cerebral Toxoplasmosis, were observed in 40 cases (20%). Diffuse microglial proliferation was noted in 104 patients (52%). Cerebral cryptococcosis was found in three patients. Progressive multifocal leukoencephalopathy was seen in 16 patients (8%). Various combinations of CNS pathological processes were found in 44 of the patients (22%). These include concomitant infections with Toxoplasma gondii and HIVRE in 13 patients; Toxoplasmosis and PCNSL in 8 patients; Toxoplasmosis with CMV and HIVRE in 4 patients; Toxoplasmosis with CMV in 2 patients; Toxoplasmosis with PCNSL and CMV in 2 patients; Toxoplasmosis with PCNSL and HIVRE in 2 patients and Toxoplasmosis with PML and HIVRE in 2 patients; Cerebral CMV with PCNSL and HIVRE in 4 patients; Cerebral CMV with HIVRE in 2 patients; PML with PCNSL in one patient; PML with HIVRE in 2 patients; and PML with PCNSL and HIVRE in one patient. Cerebrovascular lesions were found in 34 patients (17%).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7479362     DOI: 10.1016/S0344-0338(11)80730-2

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  14 in total

1.  Disrupted SOX10 function causes spongiform neurodegeneration in gray tremor mice.

Authors:  Sarah R Anderson; Inyoul Lee; Christine Ebeling; Dennis A Stephenson; Kelsey M Schweitzer; David Baxter; Tara M Moon; Sarah LaPierre; Benjamin Jaques; Derek Silvius; Michael Wegner; Leroy E Hood; George Carlson; Teresa M Gunn
Journal:  Mamm Genome       Date:  2014-11-16       Impact factor: 2.957

2.  Hidden in plain view: emergence of progressive multifocal leukoencephalopathy after treatment of CNS toxoplasmosis.

Authors:  Sarah Gheuens; Sarah H Cheeseman; Igor J Koralnik
Journal:  Acta Neurol Belg       Date:  2011-09       Impact factor: 2.396

Review 3.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 4.  Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS.

Authors:  Jonathan Pitcher; Saori Shimizu; Silvia Burbassi; Olimpia Meucci
Journal:  J Neuroimmunol       Date:  2010-06-08       Impact factor: 3.478

Review 5.  Impact of lipoxin-mediated regulation on immune response to infectious disease.

Authors:  Fabiana S Machado; Julio Aliberti
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Concomitant progressive multifocal leucoencephalopathy and primary central nervous system lymphoma expressing JC virus oncogenic protein, large T antigen.

Authors:  G L Gallia; L DelValle; C Laine; M Curtis; K Khalili
Journal:  Mol Pathol       Date:  2001-10

Review 7.  Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Authors:  Patrick Gannon; Muhammad Z Khan; Dennis L Kolson
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

8.  Morphine potentiates neuropathogenesis of SIV infection in rhesus macaques.

Authors:  Sirosh M Bokhari; Ramakrishna Hegde; Shannon Callen; Honghong Yao; Istvan Adany; Qingsheng Li; Zhuang Li; David Pinson; Hung-Wen Yeh; Paul D Cheney; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-24       Impact factor: 4.147

9.  Cryptococcosis in Acquired Immunodeficiency Syndrome Patients Clinically Confirmed and/or Diagnosed at Necropsy in a Teaching Hospital in Brazil.

Authors:  Rafael Garcia Torres; Renata Margarida Etchebehere; Sheila Jorge Adad; Adilha Rua Micheletti; Barbara de Melo Ribeiro; Leonardo Eurípedes Andrade Silva; Delio Jose Mora; Kennio Ferreira Paim; Mario León Silva-Vergara
Journal:  Am J Trop Med Hyg       Date:  2016-07-25       Impact factor: 2.345

Review 10.  Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs.

Authors:  Jeanne E Bell; Juan-Carlos Arango; Iain C Anthony
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.